• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    11/6/24 6:01:49 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDT alert in real time by email
    SC 13G/A 1 d910109dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    (Amendment No. 1)*

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-l(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

    CONDUIT PHARMACEUTICALS INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    20678X106

    (CUSIP Number)

    St George Street Capital

    Bates Wells Braithwaite

    10 Queen Street Place

    London, United Kingdom EC4R 1BE

    Attn: Stephen Scott, Chief Executive Officer

    +44 (0) 7764 50631

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    September 3, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-l(b)

    ☒ Rule 13d-l(c)

    ☐ Rule 13d-l(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 20678X106

     

     1   

     NAME OF REPORTING PERSON

     

     St George Street Capital

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     England and Wales

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON

     

     OO (Charitable foundation)


    SCHEDULE 13G

     

    Item 1(a).    Name of Issuer:
       Conduit Pharmaceuticals Inc. (formerly known as Murphy Canyon Acquisition Corp.) (the “Issuer”)
    Item 1(b).    Address of Issuer’s Principal Executive Offices (as reported by the Issuer):
      

    4995 Murphy Canyon Road, Suite 300

    San Diego, California 92123

    Item 2(a).    Name of Person Filing:
       This Amendment No. 1 (this “Amendment”) to the initial Statement on Schedule 13G, filed September 29, 2023, is filed by St George Street Capital. The foregoing entity is sometimes referred to herein as the “Reporting Person.”
    Item 2(b).    Address of Principal Business Office or, if none, Residence:
       The business address of the Reporting Person is Bates Wells Braithwaite, 10 Queen Street Place, London, United Kingdom EC4R 1BE.
    Item 2(c).    Citizenship:
       The Reporting Person is charitable foundation organized under the laws of England and Wales.
    Item 2(d).    Title of Class of Securities:
       Common Stock, $0.0001 par value per share (“Common Stock”)
    Item 2(e).    CUSIP Number:
       20678X106
    Item 3.    If this statement is filed pursuant to Rule 13d-l(b) or Rule 13d-2(b) or (c), check whether the person filing is a:
    (a) ☐    Broker or dealer registered under Section 15 of the Act;
    (b) ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c) ☐    Insurance company as defined in Section 3(a)(l9) of the Act;
    (d) ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e) ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f) ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g) ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h) ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
    (i) ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
    (j) ☐    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
    (k) ☐    Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
       Not applicable

    If filing as a non-U.S. institution in accordance with Rule 13d-l(b)(l)(ii)(J), please specify the type of institution:

    Not applicable


    Item 4.    Ownership:
    (a)    Amount beneficially owned: 0
    (b)    Percent of class: 0%
    (c)    Number of shares as to which such person has:
      

    (i) Sole power to vote or to direct the vote: 0

      

    (ii)  Shared power to vote or to direct the vote: 0

      

    (iii)  Sole power to dispose or to direct the disposition of: 0

      

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5.    Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. ☒
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person: Not Applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable.
    Item 8.    Identification and Classification of Members of the Group: Not Applicable.
    Item 9.    Notice of Dissolution of Group: Not Applicable.
    Item 10.    Certifications:
       By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Amendment is true, complete and correct.

     

    Dated: November 6, 2024
    ST GEORGE STREET CAPITAL
    By:  

    /s/ John Martin

    Name:   John Martin
    Title:   Chairman & Director
    Get the next $CDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDT
    SEC Filings

    View All

    SEC Form 10-Q filed by CDT Equity Inc.

    10-Q - CDT Equity Inc. (0001896212) (Filer)

    8/14/25 5:00:21 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-Q/A filed by CDT Equity Inc.

    10-Q/A - CDT Equity Inc. (0001896212) (Filer)

    8/14/25 4:55:12 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by CDT Equity Inc.

    8-K - CDT Equity Inc. (0001896212) (Filer)

    8/14/25 1:11:17 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fry Simon Jeremy was granted 35,000 shares, increasing direct ownership by 1,789% to 36,956 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    8/26/25 4:30:30 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Farley Chele Chiavacci was granted 35,000 shares, increasing direct ownership by 1,477% to 37,369 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    8/26/25 4:30:27 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lewis-Hall Freda C was granted 35,000 shares, increasing direct ownership by 1,010% to 38,466 units (SEC Form 4)

    4 - CDT Equity Inc. (0001896212) (Issuer)

    8/26/25 4:30:28 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Executes Cryptocurrency Treasury Reserve Strategy

    NAPLES, Fla. And CAMBRIDGE, United Kingdom, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced the strategic acquisition of 8.65252366 Bitcoin ("BTC") for an aggregate purchase price of $1,000,000 (inclusive of fees and expenses), at an average acquisition price of $115,285 per BTC. By incorporating Bitcoin into its treasury reserve strategy, CDT aims to strengthen its financial position and reinforce balance sheet resilience, while aligning with the accelerating institutional adoption of digital assets within a regulatory environment that is progressively enabling broader acceptance. "We are pleased to execute the definit

    9/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that, following its strategic review of the cryptocurrency and stablecoin market, engagement with third-party consultants and conversations with stakeholders, the Board has approved a cryptocurrency-based treasury reserve strategy to hold part of its current balance sheet, diversifying its capital management approach for the Company's assets. The decision reflects the Company's conviction that long-term exposure to digital assets presents both strategic and financial benefits for investors. The Board recognizes the significant market acti

    9/3/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms the Company's decision to pursue an artificial intelligence-led drug repurposing strategy for its portfolio. CDT, in collaboration with Sarborg, has carried out an in-depth analysis of AZD1656, utilizing an algorithmic approach that involves AI-powered disease mapping to identify repurposing opportunities against a database of ov

    8/26/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Leadership Updates

    Live Leadership Updates

    View All

    Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

    Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in

    11/19/24 4:30:00 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals to Join Russell 3000® Index

    SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat

    6/13/24 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

    Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) --  Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide

    3/19/24 7:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Financials

    Live finance-specific insights

    View All

    Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

    Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658. These filings represent a significant expansion of Conduit's intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP

    7/7/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

    Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health marketEvaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 developmentCost-efficient approach enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder valueSynergistic combination therapies under evaluation could redefine treatment standards in veterinary and human applications NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWS

    6/4/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company's application to transfer the listing of its common stock to The Nasdaq Capital Market has been approved and the Company's securities will be transferred to The Nasdaq Capital Market at the

    5/22/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    11/6/24 6:01:49 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/18/24 4:15:06 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Conduit Pharmaceuticals Inc.

    SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/11/24 6:01:23 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care